BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29757709)

  • 21. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
    Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
    Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calretinin as a blood-based biomarker for mesothelioma.
    Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
    BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
    Aguilar-Madrid G; Pesch B; Calderón-Aranda ES; Burek K; Jiménez-Ramírez C; Juárez-Pérez CA; Ochoa-Vázquez MD; Torre-Bouscoulet L; Acosta-Saavedra LC; Sada-Ovalle I; García-Figueroa J; Alvarado-Cabrero I; Castillo-González P; Báez-Saldaña AR; Pérez-Padilla JR; Osnaya-Juárez J; Rivera-Rosales RM; García-Bazán EM; Bautista-Aragón YL; Lazcano-Hernandez E; Munguía-Canales DA; Argote-Greene LM; Taeger D; Weber DG; Casjens S; Raiko I; Brüning T; Johnen G
    Int J Med Sci; 2018; 15(9):883-891. PubMed ID: 30008600
    [No Abstract]   [Full Text] [Related]  

  • 26. About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.
    Mlika M; Zorgati M; BenKhelil M; Mezni FE
    J Immunoassay Immunochem; 2019; 40(3):269-282. PubMed ID: 30810450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma.
    Tsuta K; Kato Y; Tochigi N; Hoshino T; Takeda Y; Hosako M; Maeshima AM; Asamura H; Kondo T; Matsuno Y
    Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):126-30. PubMed ID: 19516197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
    Linton A; Kao S; Vardy J; Clarke S; van Zandwijk N; Klebe S
    Asia Pac J Clin Oncol; 2013 Sep; 9(3):273-9. PubMed ID: 23167246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic procedures of pleural malignant mesothelioma: our experience.
    Stojsic J; Spasic Z; Velinovic M; Adzic T; Maric D; Todorovic V; Drndarevic N
    J BUON; 2004; 9(4):423-6. PubMed ID: 17415849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
    Panjković M; Lovrenski A; Eri Z; Usaj SK; Tegeltija D; Krcedinac J
    Vojnosanit Pregl; 2013 Nov; 70(11):1010-4. PubMed ID: 24397195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
    King J; Thatcher N; Pickering C; Hasleton P
    Histopathology; 2006 Dec; 49(6):561-8. PubMed ID: 17163840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
    Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
    Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unusual features of malignant pleural mesothelioma metastatic to the mediastinal lymph nodes.
    Wagner D; Bourne PA; Yang Q; Goldman BI; Lewis JS; Xu H
    Appl Immunohistochem Mol Morphol; 2008 May; 16(3):301-7. PubMed ID: 18301236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma.
    Granville LA; Younes M; Churg A; Roggli VL; Henderson DW; Cagle PT
    Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):75-9. PubMed ID: 15722797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
    Betta PG; Magnani C; Bensi T; Trincheri NF; Orecchia S
    Arch Pathol Lab Med; 2012 Mar; 136(3):253-61. PubMed ID: 22372901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma.
    Greillier L; Cavailles A; Fraticelli A; Scherpereel A; Barlesi F; Tassi G; Thomas P; Astoul P
    Cancer; 2007 Nov; 110(10):2248-52. PubMed ID: 17886249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma.
    Kushitani K; Amatya VJ; Okada Y; Katayama Y; Mawas AS; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y
    Histopathology; 2017 Feb; 70(3):375-384. PubMed ID: 27589012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the best way to diagnose and stage malignant pleural mesothelioma?
    Zahid I; Sharif S; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.